|
Titration curve analysis of PD-L2 mAbs to detect recombinant PD-L2 in ELISA with RF16021, RF16022, RF16023, RF16024, and RF16025 abs at decreasing concentrations. |
|
Flow cytometry analysis of PD-L2 overexpressing HEK293 cells using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 10 &956,g/ml. Blue: Untransfected HEK293 cells. Yellow: PD-L2 overexpressing HEK293 cells. |
|
Immunocytochemistry of PD-L2 in overexpressing 293 cells using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 5 &956,g/ml. |
|
Immunofluorescence of PD-L2 in overexpressing 293 cells using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 20 &956,g/ml. |
|
Immunofluorescence of PD-L2 in human tonsil tissue using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 20 &956,g/ml. |
|
Immunohistochemistry of PD-L2 in human colon carcinoma tissue using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 2 &956,g/ml. |
|
Immunohistochemistry of PD-L2 in human tonsil tissue using (A) RF16021, (B) RF16022, (C) RF16023, (D) RF16024, (E) RF16025, and (F) control mouse IgG antibody at 2 &956,g/ml. |
|
Western blot analysis of PD-L2 in overexpressing 293 cells using RF16021, RF16022, RF16023, RF16024, and RF16025 antibody at 0.5 and 1 &956,g/ml, respectively. Larger molecular weight bands represent more highly post-translationally modified PD-L2. |